CClinicalTrials.gg
Sign In
TerminatedNCT05250310SLYM IIUpdated Feb 11, 2026

The Effect of Structured Lifestyle Modification and Yoga Practice on Metabolic Processes Associated With Cardiovascular Disease

An interventional study of Chair Yoga in Coronary Artery Disease, sponsored by Icahn School of Medicine at Mount Sinai. Terminated at 1 site in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-02-11.

Sponsored by Icahn School of Medicine at Mount Sinai · Not applicable, Interventional, and Basic science

Why this study was terminated
We have closed the study as subjects were not interested in participating.
Phase
Not applicable
Study type
Interventional
Enrollment
16
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

The aim of the prospective randomized single center study is to evaluate the effect of a short-term (16 weeks) yoga program on micro RNA (miRNA) expression and cardiovascular disease (CVD) risk factors in patients with CVD.

Read the detailed description

Cardiovascular disease (CVD) and metabolic syndrome (MetS) are major public health problems in the USA and worldwide. Yoga has been proven effective in numerous studies to improve cardiovascular risk factors, with a reduction in the risk of heart attacks and strokes. MicroRNAs (miRNAs) have recently emerged as key regulators of metabolism by playing a crucial role in cholesterol and lipid metabolism, fatty acid metabolism, insulin and glucose homeostasis. Yoga has been shown to induce a dynamic shift in miRNAs and reset their target genes expression associated with metabolites and pathways connected to CVD and MetS to a normal physiological state. 120 subjects will be included in the study. After recruitment, subjects will be randomized to one of two groups: Yoga (n=60) or Control (n=60) group. Patients randomized to Yoga, will practice yoga poses in a chair for 30 min at least 3 days a week by watching video instruction for 16 weeks. Control group patients will follow standard of care (SOC) treatment. At the enrollment day and at the 16-weeks follow-up visit, 15ml of blood will be collected from all participants for miRNAs expression profile.

02

Conditions studied

  • Coronary Artery Disease

Keywords

  • Coronary artery disease
  • metabolic abnormality
  • chair yoga
  • micro RNA
03

In context

Coronary Artery Disease

5,598 studies on the registry are indexed under Coronary Artery Disease; 957 are open to participants now.

This study's enrollment of 16 is below the median of 124 across 3,436 interventional studies indexed under Coronary Artery Disease.

Browse Coronary Artery Disease studies →

Lead sponsor

Icahn School of Medicine at Mount Sinai is the lead sponsor of 764 studies on the registry; 181 are open to participants now.

Of its 121 completed or terminated interventional studies of FDA-regulated products, 82 (68%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Subjects eligible for the study are 18-80 year old adults.
  • Underwent percutaneous coronary intervention (PCI) at the catheterization lab of Mount Sinai Hospital (New York, New York) or have non-obstructive coronary artery disease and at least one CVD risk factor (hypertension, hypercholesterolemia, diabetes mellitus, or obesity) or metabolic abnormality (fasting plasma glucose ≥ 100 mg/dl, documented previous diagnosis of hypertension, serum triglycerides ≥ 150 mg/dl, or HDL cholesterol \< 40 mg/dl).
  • Subjects diagnosed with metabolic syndrome, which is defined as three or more of the following conditions: (1) Central or abdominal obesity (waist circumference > 40 inches for men and > 35 inches for women); (2) High triglycerides (≥150 mg/dL or triglycerides treatment); (3) Low HDL cholesterol (\<40 mg/dL for men and \<50 mg/dL for women) or low HDL-C treatment; (4) High blood pressure (≥130/85 mmHg) or antihypertensive medications; (5) High fasting glucose (≥100 mg/dL) or type 2 diabetes mellitus.
  • Participants must be able to willingly consent to study participation and must be able to comply with the study requirements.

Exclusion criteria

Exclusion Criteria:

  • Physical/psychological limitation or unwillingness to practice yoga,
  • Congestive heart failure, known arrthymias or prior Automated Implantable Cardioverter-Defibrillator /pacemaker or any metallic implants,
  • Rheumatological/immunological diseases,
  • History of transplant,
  • Moderate to severe chronic obstructive pulmonary disease, debilitating or severe systemic Illness,
  • Subjects who are pregnant or postpartum less than 6 months,
  • Liver disease or alcohol use of more than 7 alcoholic drinks/week in women and more than 14 drinks/week in men
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Active comparator
    Yoga

    Patients randomized to Yoga arm will practice chair yoga for 30 minutes at least three days a week for 16 weeks

    Behavioral: Chair Yoga

  • No intervention
    Standard of Care

    Control group patients will follow standard of care (SOC) treatment.

Interventions

  • BehavioralChair Yoga

    Yoga poses performed in a chair

06

What researchers measure

Primary outcomes

  1. micro RNA expression

    Time frame: End of study, at 22 months

Secondary outcomes

  1. Body weight

    Body weight, kg

    Time frame: End of study, at 22 months

  2. Waist circumference

    Waist circumference, inches

    Time frame: End of study, at 22 months

  3. Blood pressure

    blood pressure

    Time frame: End of study, at 22 months

07

Study locations

1 site
  • Mount Sinai Hospital
    New York, New York 10029, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05250310
Lead sponsor
Icahn School of Medicine at Mount Sinai
Responsible party
Annapoorna Kini (Director, Cardiac Catheterization Laboratory, Icahn School of Medicine at Mount Sinai) — Principal investigator
First posted
Feb 22, 2022
Start date
Jan 24, 2022
Primary completion
Oct 24, 2025
Completion
Oct 24, 2025
Last update
Feb 11, 2026

Study contacts

Annapoorna Kini, MD
principal investigator · MOUNT SINAI HOSPITAL

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Coronary Artery Disease→

Other studies from this sponsor

Icahn School of Medicine at Mount Sinai

Start the discussion